Opko Health Stock Price, News & Analysis

OPKO Health, Inc. (Nasdaq: OPK) will participate in the 41st Annual J.P. Morgan Healthcare Conference from January 9-12, 2023, in San Francisco. The management will conduct one-on-one meetings and present on January 11 at 4:30 p.m. Pacific time. The presentation will be available via live webcast and later for replay on the OPKO Health website. As a multinational biopharmaceutical and diagnostics company, OPKO aims to lead in rapidly growing markets through innovative technologies and development capabilities.

OPKO Health reported a net loss of $86.1 million or $0.11 per share for Q3 2022, compared to a net income of $28.7 million or $0.04 per diluted share in Q3 2021. Total revenues were $179.7 million, down from $385.8 million, largely attributed to a significant decrease in COVID-19 testing volume at BioReference Laboratories. Notably, the company’s operating loss reached $87.8 million, influenced by increased costs linked to acquisitions and product development. However, OPKO anticipates higher royalty payments related to Pfizer’s NGENLA as it gains additional pricing approvals.

OPKO Health, Inc. (NASDAQ: OPK) will report its operating and financial results for the three and nine months ended September 30, 2022, on November 8, 2022. The announcement will include a business update alongside financial results and guidance, shared during a conference call at 4:30 p.m. Eastern time. Participants are encouraged to pre-register to access the call efficiently. OPKO aims to solidify its position in rapidly growing markets through its proprietary technologies and development expertise.

OPKO Health, Inc. (NASDAQ: OPK) announces the retirement of Jon R. Cohen, M.D., as Executive Chairman and CEO of BioReference Laboratories. He will serve as an advisor until December 2022 and as a consultant for nine additional months. Craig Allen, previously President and COO, is appointed Interim CEO. Cohen, recognized for leading BioReference during the COVID-19 pandemic and establishing Scarlet Health, leaves a legacy of growth and innovation. Allen brings over 25 years of lab industry experience, aiming for long-term profitable growth.

OPKO Health reports its Q2 2022 financial results with consolidated revenues of $309.9 million, down from $442.4 million year-over-year. The company experienced an operating loss of $10.7 million, contrasted with an operating income of $5.6 million in Q2 2021. Significant highlights include the acquisition of ModeX Therapeutics for $300 million in OPKO stock and $85 million in milestone payments from Pfizer for the launch of NGENLA. Loss per share stood at $0.14, compared to $0.03 in the previous year. Cash and equivalents were at $210.5 million.

OPKO Health (NASDAQ: OPK) will report its operating and financial results for Q2 2022 on August 4, 2022, after U.S. markets close. The company will hold a conference call at 4:30 p.m. Eastern Time to discuss these results and provide financial guidance. Investors are encouraged to pre-register for easier access to the call. A replay of the conference call will be available until August 11, 2022. OPKO is focused on establishing industry-leading positions in rapidly growing markets through its innovative biopharmaceutical and diagnostics expertise.

OPKO Health, Inc. (NASDAQ: OPK) will participate in the 2022 Jefferies Healthcare Conference from June 8-10 in New York City. Management's fireside chat is scheduled for June 9 at 8:00 a.m. Eastern time, and it will be webcast live, with a replay available on OPKO’s website. This event highlights OPKO's commitment to engaging with investors and showcasing its innovative biopharmaceutical and diagnostics initiatives.

OPKO Health, Inc. (NASDAQ: OPK) reported its financial results for Q1 2022, revealing consolidated revenues of $329.2 million, down from $545.2 million in Q1 2021. The company incurred a net loss of $55.4 million, or $0.08 per share, compared to a net income of $31.1 million in the previous year. Key business highlights include the acquisition of ModeX Therapeutics for $300 million in OPKO stock and the sale of GeneDx to Sema4, which provided $150 million in cash proceeds. Notably, OPKO expects to receive $85 million in milestone payments from Pfizer in Q2 2022.

OPKO Health, Inc. (NASDAQ: OPK) has acquired ModeX Therapeutics for $300 million in OPKO common stock, significantly enhancing its product pipeline. Notable appointments include Dr. Elias Zerhouni as President and Vice Chairman, Dr. Gary Nabel as Chief Innovation Officer, and Alexis Borisy as a Board member. ModeX specializes in innovative immune therapies for cancer and infectious diseases using multi-specific antibody technologies. This acquisition aims to leverage synergies in OPKO's diagnostics and therapeutics portfolio, potentially improving patient outcomes and accelerating product development.